Centre for Preventive Medicine, Dublin City University, Dublin 9, Ireland.
Metabolism. 2011 Jul;60(7):994-1000. doi: 10.1016/j.metabol.2010.10.001. Epub 2010 Nov 18.
An increase in serum osteoprotegerin (OPG) is associated with type 2 diabetes mellitus, the severity of vascular calcification, and coronary artery disease. Obesity is a risk factor for diabetes and cardiovascular disease, but little is known about the relationship between OPG and obesity. The purpose of this study was to determine if changes in body mass index (BMI) and insulin sensitivity influence circulating OPG in healthy subjects. A total of 100 subjects (36 lean, 41 overweight, and 23 obese) with normal glucose tolerance, blood pressure, and electrocardiogram stress test result volunteered for this study. Insulin sensitivity was estimated using a 2-hour oral glucose tolerance test with oral glucose insulin sensitivity analysis. Osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL),soluble receptor activator of nuclear factor-κβ ligand (sRANKL), and adiponectin were analyzed using commercially available enzyme-linked immunosorbent assays. Osteoprotegerin (P < .01) and adiponectin (P < .001) were significantly decreased in the obese compared with lean subjects. There was no significant difference between BMI categories for TRAIL or sRANKL. Controlling for age and sex, there was a significant correlation between OPG and adiponectin (r = 0.391, P < .001), BMI (r = -0.331, P < .001), waist circumference (r = -0.268, P < .01), homeostasis model assessment of insulin resistance (r = -0.222, P < .05), and oral glucose insulin sensitivity (r = 0.221, P < .05). Both OPG and adiponectin were negatively correlated with body weight, BMI, waist circumference, and fasting plasma insulin while being positively correlated with insulin sensitivity (P < .05). Controlling for age, sex, and BMI, TRAIL was positively related to fat mass (r = 0.373, P < .001) and waist circumference (r = 0.257, P < .05). In contrast to patients with type 2 diabetes mellitus, circulating OPG is lower in obese, but otherwise healthy subjects and is positively correlated with indices of insulin sensitivity.
血清护骨素（OPG）水平的增加与 2 型糖尿病、血管钙化的严重程度和冠心病有关。肥胖是糖尿病和心血管疾病的危险因素，但人们对 OPG 与肥胖之间的关系知之甚少。本研究旨在确定体重指数（BMI）和胰岛素敏感性的变化是否会影响健康受试者的循环 OPG。共有 100 名糖耐量正常、血压正常和心电图应激试验结果正常的受试者自愿参加本研究。使用口服葡萄糖耐量试验和口服葡萄糖胰岛素敏感性分析来估计胰岛素敏感性。使用商业上可用的酶联免疫吸附试验分析护骨素、肿瘤坏死因子相关凋亡诱导配体（TRAIL）、核因子-κβ 配体可溶性受体激活剂（sRANKL）和脂联素。与瘦受试者相比，肥胖者的护骨素（P<0.01）和脂联素（P<0.001）显著降低。TRAIL 或 sRANKL 在 BMI 类别之间无显著差异。控制年龄和性别后，OPG 与脂联素呈显著正相关（r=0.391，P<0.001），与 BMI（r=-0.331，P<0.001）、腰围（r=-0.268，P<0.01）、稳态模型评估的胰岛素抵抗（r=-0.222，P<0.05）和口服葡萄糖胰岛素敏感性（r=0.221，P<0.05）呈显著负相关。OPG 和脂联素均与体重、BMI、腰围和空腹血浆胰岛素呈负相关，与胰岛素敏感性呈正相关（P<0.05）。控制年龄、性别和 BMI 后，TRAIL 与脂肪量呈正相关（r=0.373，P<0.001），与腰围呈正相关（r=0.257，P<0.05）。与 2 型糖尿病患者不同，肥胖但 otherwise 健康的受试者循环 OPG 水平较低，与胰岛素敏感性指数呈正相关。
